RIP-V improves murine survival in a sepsis model by down-regulating RNAIII expression and α-hemolysin release of methicillin-resistant Staphylococcus aureus

Pharmazie

Volumn 70, Issue 2, 2015, Pages 81-87

  Ma, Bo ^a   Zhou, Ying ^a   Li, Mingkai ^a   Yu, Qian ^a   Xue, Xiaoyan ^a   Li, Zhi ^a   Da, Fei ^a   Hou, Zheng ^a   Luo, Xiaoxing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HEMOLYSIN; ANTIINFECTIVE AGENT; OXACILLIN; PEPTIDE; PEPTIDE DERIVATIVE; RNAIII INHIBITING PEPTIDE; RNAIII INHIBITING PEPTIDE L; RNAIII INHIBITING PEPTIDE V; UNCLASSIFIED DRUG; VANCOMYCIN; BACTERIAL RNA; HEMOLYSIN; OLIGOPEPTIDE; RNAIII, STAPHYLOCOCCUS AUREUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DOWN REGULATION; IN VITRO STUDY; LIVER; LUNG PARENCHYMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SURVIVAL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; LUNG; MALE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOLOGY; SEPSIS; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; DOWN-REGULATION; HEMOLYSIN PROTEINS; LIVER; LUNG; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; RNA, BACTERIAL; SEPSIS; STAPHYLOCOCCAL INFECTIONS; SURVIVAL;

EID: 84927516707     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2015.4750     Document Type: Article

References (26)

1. Balaban N, Goldkorn T, Gov Y, Hirshberg M, Koyfman N, Matthews HR, Nhan RT, Singh B, Uziel O (2001) Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating Protein (TRAP). J Biol Chem 276: 2658-2667.
2. Balaban N, Goldkorn T, Nhan RT, Dang LB, Scott S, Ridgley RM, Rasooly A, Wright SC, Larrick JW, Rasooly R, Carlson JR (1998) Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science 280: 438-440.
3. Chen LY, Chen LK, Chang CW, Kuo SC, Li LF, Chan YJ, Wang FD (2012) Treatment of community-onset methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: a hospital-based study. Arch Gerontol Geriatr 55: 152-156.
4. Chua KY, Monk IR, Lin YH, Seemann T, Tuck KL, Porter JL, Stepnell J, Coombs GW, Davies JK, Stinear TP, Howden BP (2014) Hyperexpression of alpha-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus. BMC Microbiol 14: 31.
5. Cremieux AC, Saleh-Mghir A, Danel C, Couzon F, Dumitrescu O, Lilin T, Perronne C, Etienne J, Lina G, Vandenesch F (2014) alpha-Hemolysin, not panton-valentine leukocidin, impacts rabbit mortality from severe sepsis with methicillin-resistant Staphylococcus aureus osteomyelitis. J Infect Dis 209: 1773-1780.
6. Frohlich KS, Vogel J (2009) Activation of gene expression by small RNA. Curr Opin Microbiol 12: 674-682.
7. Ghiselli R, Giacometti A, Cirioni O, Dell'Acqua G, Bergnach C, Orlando F, Mocchegiani F, Silvestri C, Skerlavaj B, Licci A, Balaban N, Zanetti M, Scalise G, Saba V (2006) RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Shock 26: 296-301.
8. Giacometti A, Cirioni O, Ghiselli R, Dell'Acqua G, Orlando F, D'Amato G, Mocchegiani F, Silvestri C, Del Prete MS, Rocchi M, Balaban N, Saba V, Scalise G (2005) RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides 26: 169-175.
9. Gov Y, Bitler A, Dell'Acqua G, Torres JV, Balaban N (2001) RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides 22: 1609-1620.
10. Harraghy N, Kerdudou S, Herrmann M (2007) Quorum-sensing systems in staphylococci as therapeutic targets. Anal Bioanal Chem 387: 437-444.
11. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP (2011) Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 204: 340-347.
12. Hou Z, Da F, Liu B, Xue X, Xu X, Zhou Y, Li M, Li Z, Ma X, Meng J, Jia M, Wang Y, Luo X (2013) R-Thanatin inhibits growth and biofilm formation of methicillin-resistant Staphylococcus epidermidis in vivo and in vitro. Antimicrob Agents Chemother 57: 5045-5052.
13. Hou Z, Lu J, Fang C, Zhou Y, Bai H, Zhang X, Xue X, Chen Y, Luo X (2011) Underlying mechanism of in vivo and in vitro activity of C-terminal-amidated thanatin against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli. J Infect Dis 203: 273-282.
14. Korem M, Gov Y, Kiran MD, Balaban N (2005) Transcriptional profiling of target of RNAIII-activating protein, a master regulator of staphylococcal virulence. Infect Immun 73: 6220-6228.
15. McDougal LK, Fosheim GE, Nicholson A, Bulens SN, Limbago BM, Shearer JE, Summers AO, Patel JB (2010) Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother 54: 3804-3811.
16. Moreira CG, Weinshenker D, Sperandio V (2010) QseC mediates Salmonella enterica serovar typhimurium virulence in vitro and in vivo. Infect Immun 78: 914-926.
17. Ng WL, Bassler BL (2009) Bacterial quorum-sensing network architectures. Annu Rev Genet 43: 197-222.
18. Novick RP, Geisinger E (2008) Quorum sensing in staphylococci. Annu Rev Genet 42: 541-564.
19. Pang YY, Schwartz J, Thoendel M, Ackermann LW, Horswill AR, Nauseef WM (2010) agr-Dependent interactions of Staphylococcus aureus USA300 with human polymorphonuclear neutrophils. J Innate Immun 2: 546-559.
20. Raghuraman H, Chattopadhyay A (2007) Melittin: a membrane-active peptide with diverse functions. Biosci Rep 27: 189-223.
21. Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9: 117-128.
22. Rodvold KA, McConeghy KW (2014) Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 58 Suppl 1: S20-27.
23. Sakoulas G, Moellering RC Jr. (2008) Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 46 Suppl 5: S360-367.
24. Tang F, Li WH, Zhou X, Liu YH, Li Z, Tang YS, Kou X, Wang SD, Bao M, Qu LD, Li M, Li B (2014) Puerarin protects against Staphylococcus aureus-induced injury of human alveolar epithelial A549 cells via downregulating alpha-hemolysin secretion. Microb Drug Resist 20: 357-363.
25. Tavares A, Nielsen JB, Boye K, Rohde S, Paulo AC, Westh H, Schonning K, de Lencastre H, Miragaia M (2014) Insights into alpha-hemolysin (Hla) evolution and expression among Staphylococcus aureus clones with hospital and community origin. PLoS One 9: e98634.
26. Vanderpool CK, Balasubramanian D, Lloyd CR (2011) Dual-function RNA regulators in bacteria. Biochimie 93: 1943-1949.